NR1H4 and glomerulosclerosis: Farnesoid X receptor (FXR) agonists modulate SREBP1 expression, lipid metabolism, and the expression of renal profibrotic growth factor, proinflammatory cytokines, and oxidative stress enzymes and reduce glomerulosclerosis, tubulointerstitial fibrosis, and proteinuria.